awmsg logo



insulin detemir (Levemir®)


Reference No. 1427

Publication date:
13/12/2012


Last review date:
30/11/2016

Appraisal information

insulin detemir (Levemir®) solution for injection


Company: Novo Nordisk Ltd
BNF category: Endocrine system
NMG meeting date: 09/10/2012
AWMSG meeting date: 14/11/2012
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 3912
Ministerial ratification: 11/12/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Insulin detemir (Levemir®) is recommended as an option for use within NHS Wales for the treatment of diabetes mellitus in children aged 1–5 years.
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download